Policy Proposal: International Reference Pricing for Pharmaceuticals in the United States

Health
1

Background

The United States consistently faces higher prescription drug prices compared to other developed nations. This disparity is largely due to the lack of government price regulations in the U.S. pharmaceutical market, unlike many other countries in the Organization for Economic Co-operation and Development (OECD).

Proposal

We propose implementing an International Reference Pricing (IRP) system for pharmaceuticals in the United States. This policy would tie the maximum allowable price for prescription drugs in the U.S. to the lowest price offered in other OECD countries.

Key Points

  1. No pharmaceutical company shall be authorized to sell their products in the United States at a price higher than the lowest regulated price in other OECD countries.
  2. The Department of Health and Human Services (HHS) will be responsible for monitoring and enforcing this policy.
  3. Pharmaceutical companies must provide pricing data from all OECD countries where their products are sold.
  4. The policy will apply to both brand-name and generic drugs.
  5. A transition period of 2 years will be implemented to allow companies to adjust their pricing strategies.

Expected Outcomes

  1. Significant reduction in prescription drug prices for American consumers
  2. Increased access to essential medications
  3. Reduced healthcare costs for individuals, employers, and the government
  4. Potential increase in pharmaceutical innovation focused on value rather than profit maximization

Challenges and Considerations

  1. Resistance from the pharmaceutical industry
  2. Potential reduction in R&D investment
  3. Implementation and enforcement logistics
  4. International trade implications

Next Steps

  1. Conduct a comprehensive economic impact analysis
  2. Engage with stakeholders, including pharmaceutical companies, healthcare providers, and patient advocacy groups
  3. Draft detailed legislation for Congressional review
2 Likes
2
  1. No pharmaceutical company shall be authorized to sell their products in the United States at a price higher than the lowest regulated price in other OECD countries.

Yes. Something needs to be done. Along with doctor and hospital care pricing.

1 Like
3

Doctor and Hospital care pricing need to be addressed too but the pharmaceutical products is a very easy thing to address. Being myself dual citizen, I know in Europe many products that only cost a fraction of the price they are sold in the US,
It would be very quick and easy to implement this. We just need politics with courage to fight the Pharma lobbyists.